Proposed pathophysiological crosstalk between MAFLD and CKD.

<p>This schematic illustrates the proposed pathophysiological crosstalk between Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Chronic Kidney Disease (CKD). <b>Panel A depicts organ-specific mechanisms:</b> in the <i>liver</i>, steatosis (lipid-laden h...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autor: Zienab M. Saad (22676502) (author)
Další autoři: Hesham K. H. Keryakos (22676505) (author), Hala A. Hassanin (22676508) (author), Mahmoud M. Higazi (22676511) (author), Manar M. Sayed (22676514) (author), Doaa E. Ismail (22676517) (author), Safaa M. Abdelhalim (21398199) (author)
Vydáno: 2025
Témata:
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:<p>This schematic illustrates the proposed pathophysiological crosstalk between Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Chronic Kidney Disease (CKD). <b>Panel A depicts organ-specific mechanisms:</b> in the <i>liver</i>, steatosis (lipid-laden hepatocytes) progresses through inflammation (Kupffer cell activation, TNF-α/IL-6 release) to fibrosis (stellate cell activation, collagen deposition); in the <i>kidney</i>, lipotoxicity (podocyte fatty acid influx) leads to podocyte injury (effacement, apoptosis) and glomerulosclerosis (collagen IV accumulation). <b>Panel B highlights systemic mediators</b>: insulin resistance (hyperinsulinemia-driven hepatic gluconeogenesis and renal sodium retention), dyslipidemia (VLDL/ApoB glomerular deposition), and key mediators (fetuin-A, adiponectin deficiency, uric acid-induced NLRP3 activation). Bidirectional interactions amplify organ damage through direct (lipotoxicity, fibrosis) and systemic (metabolic, inflammatory) pathways, suggesting shared therapeutic targets for dual hepatic-renal protection.</p>